bezlotoxumab (Zinplava)
Jump to navigation
Jump to search
Indications
- prevention of recurrence of Clostridium difficile infection[2][3]
Mechanism of action
- binds C difficile toxin B
More general terms
References
- ↑ Wikipedia: Bezlotoxumab https://en.wikipedia.org/wiki/Bezlotoxumab
- ↑ 2.0 2.1 Merk News Release. Oct 21, 2016 FDA Approves Merck's ZINPLAVA <TM> (bezlotoxumab) to Reduce Recurrence of Clostridium difficile Infection (CDI) in Adult Patients Receiving Antibacterial Drug Treatment for CDI Who Are at High Risk of CDI Recurrence http://www.mercknewsroom.com/news-release/corporate-news/fda-approves-mercks-zinplava-bezlotoxumab-reduce-recurrence-clostridium-
- ↑ 3.0 3.1 Wilcox MH, Gerding DN, Poxton IR et al Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection. N Engl J Med 2017; 376:305-317 January 26, 2017 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/28121498 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1602615
Bartlett JG Bezlotoxumab - A New Agent for Clostridium difficile Infection. N Engl J Med 2017; 376:305-317 January 26, 2017 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/28121509 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMe1614726